Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Mereo BioPharma Group plcNASDAQ: MREO
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.61M fell 29.5% year over year, behind the -9.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.
Context
- Stock-based compensation amounted to 1519.6% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.5% toward the trailing-twelve-month pace of -9.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7.6M USD
- Year-over-year change
- +2.8%
- 4-year CAGR
- +14.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.6M | +2.8% |
| FY2024 | 2024-12-31 | 7.39M | +50.1% |
| FY2023 | 2023-12-31 | 4.92M | +3.3% |
| FY2022 | 2022-12-31 | 4.77M | +7.0% |
| FY2021 | 2021-12-31 | 4.46M | — |
Stock-Based Compensation vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.1% is the 5th highest of 10, against a peer median of -19.1%.
- Stock-based compensation amounts to 1385.0% of revenue for MREO, versus a peer median of 49.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B USD | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $14.34M USD | — | -14.0% | 1556.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M USD | +31.2% | +73.3% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M USD | -19.1% | +89.6% | — |
| LTM Mar 2026 | $11.09M USD | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $6.93M USD | -9.1% | +16.8% | 1385.0% | |
| LTM Mar 2026 | $4.96M USD | +8.1% | +18.3% | — | |
| LTM Mar 2026 | $2.88M USD | -66.7% | -9.8% | — | |
| LTM Dec 2025 | CHF 2.68M CHF | -42.8% | — | 75.0% | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
| FY2025 | A$1.16M AUD | -35.2% | -7.8% | 23.1% | |
| Peer median (excluding MREO) | — | -19.1% | +37.6% | 49.0% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.22M | (42.22M) | (29.47M) | (43.25M) | (41.88M) |
| Depreciation & Amortization | 866.47K | 889K | 1.06M | 1.09M | 622K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.46M | 4.77M | 4.92M | 7.39M | 7.6M |
| Change in Working Capital | (2.49M) | (2.35M) | (1.59M) | (369K) | (3.21M) |
| Accounts Receivables | (794.94K) | (3.47M) | 456K | (1.65M) | 1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 617K | (1.26M) | 146K | (1.38M) |
| Other Working Capital | (1.7M) | 498K | (786K) | 1.13M | (3.23M) |
| Other Non-Cash Items | (29.12M) | (9.91M) | 3.94M | 2.31M | 5.9M |
| Operating Cash Flow | (7.07M) | (48.82M) | (21.13M) | (32.83M) | (30.97M) |
| Capital Expenditures | (722.06K) | (13K) | (419K) | (699K) | (20K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 153.86K | 2M | (419K) | 0 | 0 |
| Investing Cash Flow | (568.2K) | 1.99M | (419K) | (699K) | (20K) |
| Debt Repayment | (933.95K) | 0 | (3.19M) | 0 | 0 |
| Common Stock Issued | 105.99M | 0 | 11.61M | 47M | 327.76K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (253.73K) | 200K | 24K | (853K) | (764) |
| Financing Cash Flow | 104.8M | 200K | 7.97M | 46.15M | 327K |
| Effect of Forex Changes | (1.57M) | (12.58M) | 2.82M | (233K) | 1.93M |
| Net Change in Cash | 95.59M | (59.22M) | (10.76M) | 12.38M | (28.81M) |
| Free Cash Flow | (7.79M) | (48.83M) | (21.55M) | (33.53M) | (30.99M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.